Estimating long-term overall survival with olaparib as maintenance therapy in patients with newly diagnosed advanced ovarian cancer with BRCA mutations

MLA

N. A. Avxentyev, et al. “Estimating Long-Term Overall Survival with Olaparib as Maintenance Therapy in Patients with Newly Diagnosed Advanced Ovarian Cancer with BRCA Mutations.” Опухоли Женской Репродуктивной Системы, vol. 17, no. 3, Oct. 2021, pp. 97–105. EBSCOhost, https://doi.org/10.17650/1994-4098-2021-17-3-97-105.

APA

N. A. Avxentyev, S. V. Khokhlova, M. Yu. Frolov, & A. S. Makarov. (2021). Estimating long-term overall survival with olaparib as maintenance therapy in patients with newly diagnosed advanced ovarian cancer with BRCA mutations. Опухоли Женской Репродуктивной Системы, 17(3), 97–105. https://doi.org/10.17650/1994-4098-2021-17-3-97-105

Chicago

N. A. Avxentyev, S. V. Khokhlova, M. Yu. Frolov, and A. S. Makarov. 2021. “Estimating Long-Term Overall Survival with Olaparib as Maintenance Therapy in Patients with Newly Diagnosed Advanced Ovarian Cancer with BRCA Mutations.” Опухоли Женской Репродуктивной Системы 17 (3): 97–105. doi:10.17650/1994-4098-2021-17-3-97-105.